Less than 10% of patients who could benefit from obesity jabs such as Wegovy are able to get them, warns the global health agency as it issues its initial advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable access to this class of drugs.
Based on forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"Our latest guidelines recognises that obesity is a lifelong illness that can be managed with holistic and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key obstacles to universal access to the jabs that can help people shift substantial weight, explains the organization.
Skinny Jab Scarcity
Even under the present most optimistic case, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The advice encourages nations and manufacturers to widen access, by strategies including patent sharing.
Exclusive production rights on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Drugs Function
These medications replicate a body's own hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals reduce food intake.
Patients usually begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Studies points to people may regain a significant portion a year later of halting the treatment, when their typical hunger come back.
To be above a healthy weight elevates your chance for experiencing medical conditions, like diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.
